Although Black men die of prostate cancer at twice the rate of the rest of U.S. males, this fact often is not known or considered during appointments with their primary-care clinicians to discuss a common screening test.

Nearly 50 new cancer therapies are approved every year. This is good news. “But for patients and their treating physicians, it is becoming increasingly difficult to keep track and to select the treatment methods from which the people affected—each with their very individual tumor characteristics—will benefit the most,” says Dr. Altuna Akalin, head of the Bioinformatics and Omics Data Science technology platform at the Berlin Institute for Medical Systems Biology of the Max Delbrück Center (MDC-BIMSB).